Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

FDA Extends Review Timeline For STELARA(TM) (ustekinumab) Biologic License Application By Three Months
Centocor Ortho Biotech Inc. announced that the U.S. Food and Drug Administration (FDA) has extended by three months the review timeline for the Biologic License Application (BLA) for STELARA(TM) (ustekinumab) to provide time for a full review of an amendment to the pending application. The application seeks approval to market STELARA for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
generic viagra online
Abusive Relationships Increase Women's Risk Of HIV Infection
A new study of nearly 14,000 U.S. women reveals that those who are in physically abusive relationships are at higher risk for HIV infection.
News of the day
New Approach To Prevent Antibody-Mediated Damage In Kidney Transplants
Early results from a Mayo Clinic research study demonstrate the effectiveness of a new approach to blocking an important part of the immune system that causes severe damage to some kidney transplants. Historically, these patients have been very difficult to treat successfully because their immune systems are already primed with antibodies to destroy the donor organ. These findings were presented at the American Transplant Congress.
Nutrition

New Treatments Should Be Introduced Gradually To Avoid Later Problems, Says Expert

Concerns over whether the tests a treatment undergoes before release onto the market are enough to ensure its long-term safety are raised in an editorial published by BMJ Clinical Evidence today. Dr Vijay Sharma suggests that treatments should be introduced gradually so that evidence can be built up and the treatment can find its proper niche. To illustrate this, he discusses the recent debate on the long-term safety of drug-eluting stents. Stents (small tubes) are used to unblock arteries that have become thickened by fatty deposits. They improve blood flow and reduce the risk of death from coronary artery disease. Drug-eluting stents slowly release drugs to stop blood clots blocking the stented arteries, a process called restenosis. Drug-eluting stents were used with great enthusiasm when first introduced in 2002, but since 2006 several reports have highlighted an increased risk of clotting as late as one year after treatment (known as late-stent thrombosis). But why was this risk not detected sooner, asks the author? One reason may relate to the outcomes that early clinical trials set out to measure. Another may be that trials have predominantly focused on low risk cases, yet drug-eluting stents were also used in complex cases, where the underlying risk of clotting is higher. More complex cases also require the use of more stents and longer stents, further increasing the risk of late-stent thrombosis, he explains. All adverse effects must be carefully assessed in large-scale studies, writes Dr Sharma. But they must also be balanced against the threat posed by coronary artery disease itself, and interpreted in the context of other treatment options. He concludes: "Treatments are often greeted with enthusiasm when they first appear only to fall into disfavour when adverse effects are found. Then, with time, some of these treatments return with a more limited and clearly defined use. To avoid this pattern, adverse effects should be actively sought, and treatments should be introduced gradually so that experience and evidence can be built up and the treatment can find its proper niche." British Medical Journal


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009